Kumasi Centre for Collaborative Research in Tropical Medicine, Kumasi, Ghana.
Infectious Disease Epidemiology Research Group, Kumasi Centre for Collaborative Research in Tropical Medicine, Kumasi, Ghana.
BMC Infect Dis. 2020 May 6;20(1):323. doi: 10.1186/s12879-020-05053-z.
Praziquantel (PZQ) is the standard treatment for Schistosomiasis in sub-Saharan Africa. However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment. The objective of this study was to determine the effect of three monthly doses of 60 mg/kg/day PZQ on schistosome egg count, liver and renal function during the treatment of urinary schistosomiasis in Ghana.
A nested case-control study was designed from a cohort screened for schistosomiasis; 28 schistosomiasis positive cases by microscopy matched with 53 healthy controls by age and gender. The study population was urban dwellers from the Asokwa sub-metropolitan area, Kumasi in Ghana. Participants were within the age range of 6 to 30 years. We assessed Schistosoma haematobium egg counts in urine and its associated impact on liver and renal function at baseline, treatment and post-treatment phases using serum.
Of the 28 cases and 53 controls, 78.6% and 81.1% were males respectively. Globulin levels before treatment was higher in cases [36.7 (32.8, 40.1) vrs 30.5 (22.4, 33.8), p = 0.005] at pre-treatment but not at post-treatment [35.8 (31.2, 39.1) vrs 37.4 (29.7, 43.0), p = 0.767]. Estimated cure rate was 42.9, 46.4 and 96.4% after first, second and third dose respectively. Schistosome egg counts dropped significantly (p = 0.001) from before second dose to post-treatment. Similarly, levels of alanine aminotransferase (p = 0.001), aspartate aminotransferase (p = 0.028) and gamma glutamyl transferase (p = 0.001) significantly declined towards post-treatment. Estimated glomerular filtration rate significantly improved from before second dose to post-treatment using both the Chronic Kidney Disease Epidemiology Program (p = 0.001) and 4-variable Modification of Diet in Renal Disease (p = 0.002) equations.
Treatment of urinary Schistosoma hematobium infections with a repeated high monthly dose of 60 mg/kg of praziquantel for 3 months is safe and effective.
吡喹酮(PZQ)是撒哈拉以南非洲地区血吸虫病的标准治疗方法。然而,有证据表明,在血吸虫感染中,吡喹酮治疗失败与潜在的肾损伤有关。本研究的目的是确定在加纳进行尿路血吸虫病治疗时,每月 3 次 60mg/kg/天 PZQ 对血吸虫卵计数、肝肾功能的影响。
对筛查出的血吸虫病队列进行嵌套病例对照研究;用显微镜检查确定 28 例血吸虫病阳性病例,然后根据年龄和性别与 53 例健康对照匹配。研究人群为加纳库马西阿索卡次大都市地区的城市居民,年龄在 6 至 30 岁之间。我们使用血清评估基线、治疗和治疗后阶段的尿中血吸虫卵计数及其对肝肾功能的影响。
在 28 例病例和 53 例对照中,男性分别占 78.6%和 81.1%。治疗前,病例组球蛋白水平较高[36.7(32.8,40.1)比 30.5(22.4,33.8),p=0.005],但治疗后球蛋白水平没有差异[35.8(31.2,39.1)比 37.4(29.7,43.0),p=0.767]。第一次、第二次和第三次剂量后的估计治愈率分别为 42.9%、46.4%和 96.4%。第二次剂量前至治疗后,血吸虫卵计数显著下降(p=0.001)。同样,丙氨酸氨基转移酶(p=0.001)、天冬氨酸氨基转移酶(p=0.028)和γ-谷氨酰转移酶(p=0.001)水平也在治疗后显著下降。使用慢性肾脏病流行病学合作(Chronic Kidney Disease Epidemiology Collaboration,CKD-EPI)公式和 4 变量改良肾脏病饮食研究(4-variable Modification of Diet in Renal Disease,MDRD)公式,肾小球滤过率在第二次剂量前至治疗后均显著改善(p=0.001)。
重复每月 60mg/kg 吡喹酮高剂量治疗 3 个月治疗尿路血吸虫病感染是安全有效的。